DNA Vaccination: Using the Patient's Immune System to Overcome Cancer
Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or develo...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/169484 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566922448732160 |
|---|---|
| author | Georg Eschenburg Alexander Stermann Robert Preissner Hellmuth-Alexander Meyer Holger N. Lode |
| author_facet | Georg Eschenburg Alexander Stermann Robert Preissner Hellmuth-Alexander Meyer Holger N. Lode |
| author_sort | Georg Eschenburg |
| collection | DOAJ |
| description | Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients. |
| format | Article |
| id | doaj-art-d6c23dd3c3e2411890247abc6f87e6b4 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-d6c23dd3c3e2411890247abc6f87e6b42025-02-03T01:02:46ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/169484169484DNA Vaccination: Using the Patient's Immune System to Overcome CancerGeorg Eschenburg0Alexander Stermann1Robert Preissner2Hellmuth-Alexander Meyer3Holger N. Lode4Experimental Oncology Group, Department of Pediatrics, Charité-University Medicine Berlin, 13353 Berlin, GermanyExperimental Oncology Group, Department of Pediatrics, Charité-University Medicine Berlin, 13353 Berlin, GermanyStructural Bioinformatics Group, Institute for Physiology, Charité-University Medicine Berlin, 14195 Berlin, GermanyStructural Bioinformatics Group, Institute for Physiology, Charité-University Medicine Berlin, 14195 Berlin, GermanyDepartment of Pediatric Hematology and Oncology, University of Greifswald, 17475 Greifswald, GermanyCancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.http://dx.doi.org/10.1155/2010/169484 |
| spellingShingle | Georg Eschenburg Alexander Stermann Robert Preissner Hellmuth-Alexander Meyer Holger N. Lode DNA Vaccination: Using the Patient's Immune System to Overcome Cancer Clinical and Developmental Immunology |
| title | DNA Vaccination: Using the Patient's Immune System to Overcome Cancer |
| title_full | DNA Vaccination: Using the Patient's Immune System to Overcome Cancer |
| title_fullStr | DNA Vaccination: Using the Patient's Immune System to Overcome Cancer |
| title_full_unstemmed | DNA Vaccination: Using the Patient's Immune System to Overcome Cancer |
| title_short | DNA Vaccination: Using the Patient's Immune System to Overcome Cancer |
| title_sort | dna vaccination using the patient s immune system to overcome cancer |
| url | http://dx.doi.org/10.1155/2010/169484 |
| work_keys_str_mv | AT georgeschenburg dnavaccinationusingthepatientsimmunesystemtoovercomecancer AT alexanderstermann dnavaccinationusingthepatientsimmunesystemtoovercomecancer AT robertpreissner dnavaccinationusingthepatientsimmunesystemtoovercomecancer AT hellmuthalexandermeyer dnavaccinationusingthepatientsimmunesystemtoovercomecancer AT holgernlode dnavaccinationusingthepatientsimmunesystemtoovercomecancer |